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Cutaneous warts are common.
1–3 Up to one-third of
primary school children have warts, of which two-
thirds resolve within two years.4,5 Because warts fre-
quently result in discomfort,6 2% of the general population
and 6% of school-aged children each year present with
warts to their family physician.7,8 The usual treatment is
cryotherapy with liquid nitrogen or, less frequently, topical
application of salicylic acid.9–12 Some physicians choose a
wait-and-see approach because of the benign natural course
of warts and the risk of side effects of treatment.10,11
A recent Cochrane review on treatments of cutaneous
warts concluded that available studies were small, poorly
designed or limited to dermatology outpatients.10,11 Evidence
on cryotherapy was contradictory,13–18 whereas the evidence
on salicylic acid was more convincing.19–23 However, studies
that compared cryotherapy and salicylic acid directly showed
no differences in effectiveness.24,25 The Cochrane review
called for high-quality trials in primary care to compare the
effects of cryotherapy, salicylic acid and placebo.
We conducted a three-arm randomized controlled trial to
compare the effectiveness of cryotherapy with liquid nitrogen,
topical application of salicylic acid and a wait-and-see approach
for the treatment of common and plantar warts in primary care.
Methods
Participants
Between May 1, 2006, and Jan. 26, 2007, 30 family practices
from the Leiden Primary Care Research Network in the
Netherlands invited all patients aged four years and older who
attended the clinic with one or more new cutaneous warts to
participate. We defined new cutaneous warts as those on the
skin that were diagnosed in family practice and had not been
treated by a physician or dermatologist in the previous year,
regardless of previous self-treatment with over-the-counter
medication. We excluded immunocompromised patients and
patients with genital warts, seborrheic warts or warts larger
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Background: Cryotherapy is widely used for the treatment of
cutaneous warts in primary care. However, evidence favours
salicylic acid application. We compared the effectiveness of
these treatments as well as a wait-and-see approach.
Methods: Consecutive patients with new cutaneous warts
were recruited in 30 primary care practices in the Nether-
lands between May 1, 2006, and Jan. 26, 2007. We randomly
allocated eligible patients to one of three groups: cryother-
apy with liquid nitrogen every two weeks, self-application of
salicylic acid daily or a wait-and-see approach. The primary
outcome was the proportion of participants whose warts
were all cured at 13 weeks. Analysis was on an intention-to-
treat basis. Secondary outcomes included treatment adher-
ence, side effects and treatment satisfaction. Research nurses
assessed outcomes during home visits at 4, 13 and 26 weeks.
Results: Of the 250 participants (age 4 to 79 years), 240 were
included in the analysis at 13 weeks (loss to follow-up 4%).
Cure rates were 39% (95% confidence interval [CI] 29%–51%)
in the cryotherapy group, 24% (95% CI 16%–35%) in the sali-
cylic acid group and 16% (95% CI 9.5%–25%) in the wait-and-
see group. Differences in effectiveness were most pronounced
among participants with common warts (n = 116): cure rates
were 49% (95% CI 34%–64%) in the cryotherapy group, 15%
(95% CI 7%–30%) in the salicylic acid group and 8% (95% CI
3%–21%) in the wait-and-see group. Cure rates among the
participants with plantar warts (n = 124) did not differ signifi-
cantly between treatment groups.
Interpretation: For common warts, cryotherapy was the
most effective therapy in primary care. For plantar warts,
we found no clinically relevant difference in effectiveness
between cryotherapy, topical application of salicylic acid or
a wait-and-see approach after 13 weeks. (ClinicalTrial.gov
registration no. ISRCTN42730629)
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teria and agreed to participate were visited at home by a
trained research nurse, who confirmed their eligibility.
Informed consent (child as well as parental informed consent
for participants less than 18 years of age) was obtained, and
baseline characteristics were collected.
Study design and randomization
We stratified patients by location of warts: plantar (warts on
the soles of the feet) or common (warts on the hands or other
locations).26 Participants who had both plantar and common
warts were stratified according to where the majority of their
warts were located. We used opaque, sealed envelopes that
were numbered based on a computerized randomization list
delivered by an independent statistician to conceal allocation.
After stratification by location of warts and by number of
warts (< six warts v. ≥ six warts), random allocation of partic-
ipants to treatment groups was done without blocking. The
study protocol was approved by the medical ethical commit-
tee of the Leiden University Medical Center.
Treatment protocols
One of us (K.Z.) trained all participating family physicians
and assistants working in their practices in the three 13-week
treatment protocols, which were designed to reflect best prac-
tice.10,24 Training consisted of a one-hour interactive practical
session, during which all tools and techniques were demon-
strated; real warts were not used in the  demonstrations.
For cryotherapy, we used a high-intensity regimen of one
session every two weeks until all warts were completely
gone. During each session, the participant received three ser-
ial applications in which a wad of cotton wool saturated with
liquid nitrogen was moved around on the wart. Each applica-
tion was executed until a frozen halo of 2 mm around the base
of the wart appeared (usually after 2–10 seconds).
For the topical application of salicylic acid, we used a
white petroleum jelly containing 40% salicylic acid. We
chose this concentration to provide a stronger treatment than
over-the-counter products, which usually contain 17% sali-
cylic acid. Participants assigned to this group were asked to
apply the salicylic acid every day until the warts were com-
pletely gone. They were instructed to cover the surrounding
skin with tape to protect healthy skin and apply the salicylic
acid on top of the wart with another piece of tape. Before
each subsequent daily application, they used a file to pare the
softened surface area of the wart.
Participants assigned to the wait-and-see group were
informed about the benign natural course of warts and were
advised not to undergo treatment (apart from over-the-counter
medication) for at least 13 weeks.
After the 13-week treatment period, all participants who
still had warts could switch to another treatment according to
their own preferences. Participants were free to use over-the-
counter medication during the entire follow-up period but
were asked to report all usage.
Outcome measures
Trained research nurses assessed outcomes during home vis-
its at 4, 13 and 26 weeks of follow-up, independently of the
treating physicians. A wart was considered cured if it was
no longer visible (skin colour and skin lines were re-
 established) and could not be palpated anymore by hand.
The primary outcome measure was the proportion of partici-
pants whose warts were all cured at 13 weeks. Research
nurses assessed side effects, newly developed warts (which
were not included in the primary outcome assessment) and
adherence to treatment. Treatment adherence was consid-
ered adequate if participants had received cryotherapy at
least every three weeks, had self-administered salicylic acid
at least four days per week and had not undergone any co-
intervention (treatment of warts other than over-the-counter
medication).
In addition, participants were asked to rate treatment bur-
den using a 10-point scale (1 = no burden, 10 = the worst
imaginable burden). A scores of six or higher was considered
to reflect a substantial burden. Participants rated treatment
satisfaction using a five-point scale (one = very unsatisfied,
five = very satisfied); those with a score of four or five were
considered to be satisfied.
Research nurses, family physicians and participants were
not blinded to treatment allocation. For quality control, 5% of
the assessments were directly supervised by experienced fam-
ily physicians (J.E. and K.Z.).
Statistical analysis
We chose a sample size that would provide 80% power, at a
significance level of 5%, to detect an absolute increase in the
cure rate of 20% between the two active treatment groups.
Based on a literature review, we expected salicylic acid to be
most effective, with a 70% cure rate.10,11 A total of 91 patients
were required per treatment arm.
We used the χ2 test for all comparisons of cure rates and
percentages. In our primary analysis, we compared cure rates
between the three treatment arms on an intention-to-treat
basis. We also calculated relative risks, risk differences and
numbers needed to treat for cryotherapy versus salicylic acid,
cryotherapy versus wait-and-see approach, and salicylic acid
versus wait-and-see approach. 
In secondary analyses, we compared cure rates between
the three study arms (a) with patients lost to follow-up consid-
ered not cured, (b) after excluding patients who had both
plantar and common warts, (c) at 26 weeks’ follow-up,
(d) using individual warts as the unit of analysis instead of
patients and (e) per protocol cure rates based on reported
treatment adherence. 
Subgroup analyses were pre-planned for location of warts
(common wart group v. plantar wart group), age clusters (4–
12 years v. ≥ 12 years), number of warts per participant, and
duration of warts (≤ six months v. > six months). We formally
tested for effect modification of treatment by location of
warts using a logistic regression model. 
Lastly, we compared the percentages of patients with side
effects and considerable treatment burden between the two
active treatment arms, and the percentages of patients satis-
fied with treatment between the three arms.
An abridged version of our study protocol can be found at
www.controlled-trials.com/ISRCTN42730629/warts.
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Results
Patient characteristics
Of 303 patients recruited, we excluded 53, mainly because
they had already received treatment in the previous year or
refused to participate (Figure 1). We randomly assigned the
remaining 250 participants to the cryotherapy (n = 80), topi-
cal salicylic acid (n = 84) and wait-and-see (n = 86) groups.
Baseline characteristics did not differ significantly between
the groups (Table 1). Seven per cent of the participants
reported that they had received treatment for warts more than
one year before enrolment; 35% reported that they had
• Lost to follow-up  n = 4
• Stopped treatment
protocol  n = 17
- Treatment hindrance n = 9
- Side effects n = 2
- Lack of confidence n = 1
- Other reason n = 5
• Lost to follow-up  n = 4
• Stopped treatment
protocol  n = 7
- Treatment hindrance
n = 1
- Lack of confidence n = 6
Included in primary 
intention-to-treat
analysis at 13 weeks
n = 76
Included in primary 
intention-to-treat 
analysis at 13 weeks
n = 82
Included in primary 
intention-to-treat 
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• Switched to:
- Salicylic acid n = 8
- Combination n = 3
- Wait and see n = 21
• Continued salicylic
acid n = 12
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- Combination n = 0
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Figure 1: Selection of patients for the study.
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treated their warts with one or more of the following over-
the-counter medications or methods in the past with no suc-
cess: dimethyl ether propane cryotherapy (18%), ointment
containing salicylic acid at a concentration lower than the
study ointment (12%), cutting away the warts themselves
(6%) and other alternatives (6%). At study entry, 34% of the
participants stated that they preferred cryotherapy, 35% sali-
cylic acid and 4% a wait-and-see approach (no preference
given by 27%).
Of the 250 participants, 122 (49%) were stratified into the
common wart group and 128 (51%) into the plantar wart
group. In the common wart group, 103 participants (84%) had
warts on their hands, 19 (16%) had them on parts of the body
other than hands or soles of the feet, and 13 (11%) also had
plantar warts. In the plantar wart group, 22 participants (17%)
also had common warts. Baseline characteristics were similar
between the common and plantar wart groups except for age
distribution and duration of warts.
Follow-up and treatment adherence
At 13 weeks, 10 participants (4%) were lost to follow up (8
refused further participation, 1 had entered by error because
the wart was diagnosed as a seborrheic wart, and 1 was lost
for unknown reasons). Overall, 48 (20%) of the remaining
240 participants stopped the assigned treatment protocol (see
Appendix 1, available at www.cmaj.ca/cgi/content /full /cmaj
.092194 /DC1). During the 13-week follow-up period, 61 par-
ticipants (25%) had one or more new warts; no participants
were referred to dermatology outpatient clinics.
Effectiveness of treatment
At 13 weeks, the cure rates were 39% (95% confidence inter-
val [CI] 29%–51%) after cryotherapy, 24% (95% CI 16%–
35%) after salicylic acid and 16% (95% CI 9.5%–25%) after
the wait-and-see protocol, for a relative risk of 1.6 (95% CI
1.0–2.6) for cryotherapy versus salicylic acid. Because the
effectiveness of treatments differed between the common
wart group and the plantar wart group (p for interaction
0.007), we report outcomes for all patients as well as by loca-
tion of warts (Tables 2 and 3).
In the common wart group, cryotherapy was most effec-
tive, with a cure rate of 49% (95% CI 34%–64%) at 13 weeks
(Tables 2 and 3). Further stratification by age and by duration
of warts gave similar findings.
In the plantar wart group, the cure rate at 13 weeks did not
differ between the treatment arms (Tables 2 and 3). Further
stratification revealed that cure rates were considerably lower
among participants 12 years and older than among younger
participants. Also, cure rates were lower among participants
whose warts had been present for six or more months at base-
line than among those whose warts had been present for a
shorter duration (Table 2).
Table 1: Baseline characteristics of 250 patients with cutaneous warts randomly assigned to one of three treatment arms 
 Treatment arm; no. (%) of participants* 
Characteristic 
Cryotherapy 
n = 80 
Topical salicylic acid 
n = 84 
Wait-and-see approach 
n = 86 
Sex, female 45 (56) 54 (64) 50 (58) 
Age, yr       
4–12 33 (41) 36 (43) 39 (45) 
≥ 12 47 (59) 48 (57) 47 (55) 
No. of warts, median (IQR)   2 (1–3) 2 (1–4)   2 (1–5) 
Size of warts, mm, median (IQR)   4 (3–5) 4 (3–5)   4 (3–5) 
Hindrance† 55 (69) 63 (75) 70 (81) 
Location of warts‡       
 Plantar (soles of the feet) 39 (49) 44 (52) 45 (52) 
 Common (hands or other) 41 (51) 40 (48) 41 (48) 
Duration of warts, mo       
 < 6 31 (39) 37 (44) 34 (40) 
 ≥ 6 49 (61) 47 (56) 52 (60) 
Treatment preference at baseline       
Cryotherapy 33 (41) 24 (29) 29 (34) 
Salicylic acid 22 (28) 33 (39) 32 (37) 
Wait-and-see approach   6   (8) 2   (2)   2   (2) 
No preference 19 (24)§ 25 (30) 23 (27) 
Note: IQR = Interquartile range. 
*Unless stated otherwise. 
†Presence of pain, irritation or esthetic annoyance of warts. 
‡Number of participants with common warts and number of participants with plantar warts were equivalent by chance. 
§Sum of percentages is not equal to 100 because of rounding. 
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Table 3: Relative measures of effect between the three treatment arms at 13 weeks, by location of warts (n = 240) 
Variable Relative risk (95% CI) Risk difference (95% CI) 
Number needed to treat 
for benefit (95% CI)* 
All participants (n = 240)    
Cryotherapy v. wait and see 2.49 (1.41 to 4.41) 0.24   (0.10 to 0.37) 4.2 (2.7 to 9.9) 
Salicylic acid v. wait and see 1.54 (0.82 to 2.88) 0.09 (–0.04 to 0.21) 12 (NNTB 4.8 to ∞ to NNTH 27) 
Cryotherapy v. salicylic acid 1.62 (1.01 to 2.59) 0.15   (0.01 to 0.29)  6.6 (3.4 to 145) 
Common warts (n =116)    
Cryotherapy v. wait and see 6.17 (1.99 to 19.16) 0.41   (0.23 to 0.59) 2.4 (1.7 to 4.4) 
Salicylic acid v. wait and see 1.95 (0.52 to 7.24) 0.07 (–0.07 to 0.22) 13 (NNTB 4.6 to ∞ to NNTH 15) 
Cryotherapy v. salicylic acid 3.17 (1.42 to 7.07) 0.33   (0.14 to 0.53) 3.0 (1.9 to 7.1) 
Plantar warts (n = 124)    
Cryotherapy v. wait and see 1.31 (0.63 to 2.73) 0.07 (–0.12 to 0.26)  14 (NNTB 3.8 to ∞ to NNTH 8.2) 
Salicylic acid v. wait and see 1.43 (0.72 to 2.87) 0.10 (–0.09 to 0.29) 10 (NNTB 3.5 to ∞ to NNTH 11) 
Cryotherapy v. salicylic acid 0.91 (0.47 to 1.76) –0.03 (–0.23 to 0.18)  35 (NNTB 5.7 to ∞ to NNTH 4.3) 
Note: CI = confidence interval, NNTB = number needed to treat for benefit, NNTH = number needed treat for harm. 
*Where the 95% CI of the risk difference overlaps zero, the corresponding 95% CI of the number needed to treat includes infinity (∞) and therefore is expressed 
as a range from NNTB(benefit) to ∞ to NNTH(harm). 
Table 2: Effectiveness of treatments at 13 weeks, by location of warts (n = 240) 
 Treatment arm; no. (%) of participants cured*  
 Cryotherapy  Salicylic acid Wait and see  
Variable n/N† % (95% CI) n/N† % (95% CI) n/N† % (95% CI) p value‡ 
All participants (n = 240) 30/76 39 (29–51) 20/82 24 (16–35) 13/82 16 (10–25) 0.001 
Age, yr           
4–12 16/31  52 (35–68) 15/36  42 (27–58) 11/38  29 (17–45) 0.056 
≥ 12 14/45 31 (20–46)   5/46 11 (5–23)   2/44   5 (1–15) 0.001 
Duration of warts, mo           
< 6 19/30 63 (46–78) 14/37 38 (24–54) 10/32 31 (18–49) 0.012 
≥ 6 11/46  24 (14–38)   6/45  13 (6–26)   3/50    6 (2–16) 0.012 
Common warts (n = 116) 19/39 49 (34–64)   6/39 15 (7–30)   3/38   8 (3–21) < 0.001 
Age, yr           
4–12   6/12 50 (25–75)   2/12 17 (5–45)   1/15   7 (2–25) 0.010 
≥ 12 13/27 48 (31–66)   4/27 15 (6–32)   2/23   9 (2–27) 0.001 
Duration of warts, mo           
< 6 10/12 83 (55–95)   2/11 18 (5–48)   2/13 15 (4–42) 0.001 
≥ 6   9/27  33 (19–52)   4/28  14 (6–31)   1/25    4 (< 1–20) 0.006 
Plantar warts (n = 124) 11/37 30 (17–46) 14/43 33 (20–47) 10/44 23 (13–37) 0.46 
Age, yr           
4–12 10/19 53 (32–73) 13/24 54 (35–72) 10/23 43 (26–63) 0.54 
≥ 12   1/18   6 (< 1–26)   1/19   5 (< 1–25)   0/21   0 (0–15) 0.34 
Duration of warts, mo           
< 6   9/18 50 (29–71) 12/26 46 (29–65)   8/19  42 (23–64) 0.63 
≥ 6   2/19 11 (3–31)   2/17  12 (3–34)   2/25    8 (2–25) 0.77 
Note: CI = confidence interval. 
*A participant was considered cured when all warts present at baseline were gone at follow-up. 
†Number of participants cured / number of participants in intention-to-treat analysis at 13 weeks, and percentages of participants cured.  
‡Two-sided χ2, linear-by-linear association, comparing three treatment groups. 
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Sensitivity analysis
The results at 26 weeks were concordant with the results at 13
weeks (see Appendix 2, available at www.cmaj.ca/cgi/content
/full /cmaj .092194/DC1). The same was true when we consid-
ered that all patients lost to follow-up were not cured, or when
we excluded participants with both common and plantar warts
from the analysis. Per-protocol analysis and analysis of the cure
rate of individual warts at 13 weeks showed the same signifi-
cant results as our primary analysis (see Appendices 3 and 4,
available at www.cmaj.ca /cgi /content /full /cmaj .092194/DC1) .
Side effects and treatment satisfaction
In both wart groups, participants experienced more side
effects after cryotherapy than after topical salicylic acid appli-
cation (see Appendix 5, available at  www.cmaj.ca /cgi /content
/full /cmaj.092194/DC1). The side effects included pain, blis-
tering, scarring, skin irritation, skin pigmentation and crust. In
the common wart group, 31% (95% CI 19%–46%) of the par-
ticipants reported considerable treatment burden after
cryotherapy and 54% (95% CI 39%–68%) after salicylic acid
treatment (p = 0.040). Furthermore, 69% (95% CI 53%–82%)
of participants were satisfied with treatment after cryotherapy,
as compared with 24% (95% CI 13%–39%) after salicylic
acid treatment and 22% (95% CI 12%–38%) after the wait-
and-see protocol (p < 0.001). In the plantar wart group, there
were no differences in treatment burden or satisfaction
between the three treatment groups.
Interpretation
In this pragmatic three-arm randomized controlled trial con-
ducted in family practices, we found that cryotherapy was the
most effective therapy for common warts (mainly on hands),
with 49% of patients cured after 13 weeks. Despite the fact
that cryotherapy caused more frequent and more severe side
effects than topical salicylic acid application, patients were
most satisfied when treated with cryotherapy. For plantar
warts, we found no clinically relevant difference between the
treatment arms. Regardless of treatment, children with plantar
warts showed relatively high cure rates (about 50%), whereas
plantar warts in adolescents and adults were highly persistent
(cure rates of about 5%).
Although our overall relative risk of 1.5 between salicylic
acid treatment and the wait-and-see protocol was similar to the
relative risk of 1.6 from pooled data in the recent Coch rane
review, our overall cure rates of 24% in the salicylic acid group
and 16% in the wait-and-see group were lower than the cure
rates of 73% and 48% in the Cochrane review at similar follow-
up.10,11 This marked difference is most likely due to variation in
study design and study population. Our primary care setting,
pragmatic design, wide inclusion criteria, excellent follow-up
and intention-to-treat analysis led to results that were easy to
interpret and directly applicable to daily practice in primary
care. In contrast, the two other studies comparing cryotherapy
and salicylic acid treatment, which involved dermatology outpa-
tients, excluded patients who had more than five warts, those
with warts on locations other than the location under investiga-
tion, and nonattending or noncompliant patients (in our study
20% of participants included in the analysis were noncompli-
ant).24,25 Other factors may also be at play, such as age of the
patients and duration of warts before treatment, which our study
showed to be significantly associated with cure rates.
Our follow-up at 26 weeks showed that the effects of treat-
ment of common warts were sustainable. In the plantar wart
group, in contrast to statistically equal effectiveness at 13
weeks, both of the active treatments might have higher cure
rates than a wait-and-see approach in the long term. These
findings suggest that the effect of active treatments on plantar
warts is delayed or that more aggressive treatment is needed
because of the callosity overlying the warts.14
Limitations
As in daily practice, salicylic acid was applied by the partici-
pants themselves, which could reduce effectiveness compared
with treatments applied by health professionals. However, we
explicitly recorded participants’ adherence to standardized
treatment protocols, and intention-to-treat cure rates were
concordant with results of the per-protocol analyses.
The participating patients and family practices were aware
of the treatment allocations, because the pragmatic study
design and treatment options did not secure realistic blinding.
Furthermore, the research nurses who assessed outcomes
were aware of the treatment allocations, because the appear-
ance of the skin after treatment usually revealed the specific
treatment and because the large proportion of children often
spontaneously reported the specific treatment.
Conclusion
Although earlier evidence favoured topical salicylic acid appli-
cation over cryotherapy for the treatment of cutaneous warts,
the results of our randomized controlled trial provides evi-
dence to support the use of cryotherapy over salicylic acid
treatment, for common warts only. For plantar warts, we found
no clinically relevant difference between cryotherapy, salicylic
acid treatment or a wait-and-see approach after 13 weeks.
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